Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.
REGN has been the subject of several other reports. JPMorgan Chase & Co. raised their price objective on shares of Regeneron Pharmaceuticals from $455.00 to $457.00 and gave the stock a “neutral” rating in a report on Wednesday. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Jefferies Group restated a “hold” rating and issued a $500.00 price objective (up from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, September 29th. Finally, Evercore ISI lowered their price objective on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a report on Thursday, November 16th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $471.19.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $17.48 on Friday, reaching $374.36. 1,426,670 shares of the company’s stock traded hands, compared to its average volume of 681,361. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals has a twelve month low of $340.96 and a twelve month high of $543.55. The stock has a market capitalization of $38,430.00, a price-to-earnings ratio of 34.00, a PEG ratio of 1.50 and a beta of 1.52.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Schaper Benz & Wise Investment Counsel Inc. WI increased its position in shares of Regeneron Pharmaceuticals by 27.4% during the fourth quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 12,998 shares of the biopharmaceutical company’s stock valued at $4,887,000 after acquiring an additional 2,794 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $1,417,000. Hudson Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $287,000. Hennessy Advisors Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $756,000. Finally, Steward Partners Investment Advisory LLC increased its position in shares of Regeneron Pharmaceuticals by 495.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 307 shares in the last quarter. 66.82% of the stock is owned by institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.